Now Approved: AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) – 7/31/23

Funded and Developed by GSK:

NOW APPROVED:

Coding and Pricing:

Please take a moment to update any of your reimbursement, billing, and ordering systems to reflect this change. 

*Wholesale acquisition cost (or WAC), also known as list price, is the price to wholesalers and warehousing chains, not including prompt pay, stocking or distribution allowances, or other discounts, rebates, or chargebacks. WAC may not represent prices charged to other customers, including specialty distributors, and is not the price that most patients pay for the product. For more information on the prices patients pay, please check with the patient's healthcare provider. WAC price as of 07/23.

Indication

AREXVY is indicated for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus in individuals 60 years of age and older.



Important Safety Information

• AREXVY is contraindicated in anyone with a history of a severe allergic reaction (eg, anaphylaxis) to any component of AREXVY
• Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of AREXVY
• Syncope (fainting) may occur in association with administration of injectable vaccines, including AREXVY. Procedures should be in place to avoid injury from fainting
• Immunocompromised persons, including those receiving immunosuppressive therapy, may have a diminished immune response to AREXVY​
• The most commonly reported adverse reactions (≥10%) were injection site pain (60.9%), fatigue (33.6%), myalgia (28.9%), headache (27.2%), and arthralgia (18.1%)
• Vaccination with AREXVY may not result in protection of all vaccine recipients

Please see full Prescribing Information

Reference: 1. Prescribing Information for AREXVY.

Questions About AREXVY?

Call: 1-877-AREXVY1 (1-877-273-9891)

Available Monday - Friday   8:30 am - 5:30 pm ET



Trademarks are property of their respective owners.